Lenvatinib Capsules

DRUG6 trials

Sponsors

Evergreen Therapeutics, Inc., Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Tianjin Medical University Second Hospital, Asan Medical Center, National Cancer Institute, Naples

Conditions

Advanced Endometrial CancerGISTHepatocellular CarcinomaPrecision MedicineSolid TumorVulva Cancer

Phase 1

Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients

RecruitingNCT07096609

Asan Medical CenterGIST

Start: 2025-10-29End: 2027-12-31Target: 48Updated: 2026-04-03

Phase 2

Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

CompletedNCT05101629

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestHepatocellular Carcinoma

Start: 2022-05-11End: 2025-06-30Updated: 2025-07-23

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Not yet recruitingNCT05106127

Evergreen Therapeutics, Inc.Advanced Endometrial Cancer

Start: 2026-08-31End: 2027-03-31Target: 28Updated: 2025-12-08

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

RecruitingNCT06739395

Tianjin Medical University Second HospitalPrecision Medicine, Solid Tumor

Start: 2024-11-01End: 2027-05-01Target: 300Updated: 2024-12-18

Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01

RecruitingNCT07290894

National Cancer Institute, NaplesVulva Cancer

Start: 2026-03-12End: 2031-10-01Target: 80Updated: 2026-04-02

Phase 3

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Not yet recruitingNCT05077215

Evergreen Therapeutics, Inc.Advanced Endometrial Cancer

Start: 2026-12-31End: 2027-12-31Target: 450Updated: 2025-12-08